References in periodicals archive ?
InterMune Pharmaceuticals (Nasdaq: ITMN), Burlingame, Calif., has announced financial results for the second quarter, ended June 30, 2000.
Tickers featured: AMGN, ARDS, BGEN, CHIR, DNA, DSCO, ENCY, GILD, GSK, IMCL, INGN, ITMN, MAS, NVS, OSIP, RDS, TNOX, TRMS, UTHR.
(PAV314) W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).
Tickers featured: ABGX, ABT, ADRX, AFFX, AMGN, AMRI, APPX, BMY, CHF, CPTS, CRA, DNA, GILD, HGSI, IDPH, IMCL, IMNX, ITMN, LLY, MEDI, MEDX, MYGN, ODSY, PDLI, SGP, SRA, VRTX.
7 October 2010 - US biotechnology company InterMune Inc (NASDAQ: ITMN) said yesterday it has sold worldwide development and commercialisation rights to danoprevir to Hoffman-La Roche Inc and F.
(PAL232) W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).
1 February 2010 - US-based biotech company InterMune Inc (NASDAQ: ITMN) said today that the US Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) is scheduled to discuss the company's New Drug Application (NDA) for pirfenidone on 9 March 2010.
Tickers featured: AMLN, AMT, AVIR, CORR, CYH, EMLX, HOTT, ITMN, LPNT, MCDTA, OSIP, REGN, SBAC, SITE, SUPG, TXBI, UHS.
Tickers featured: AACB, AFCI, ALA, BFT, CTLM, DSL, GYMB, ITMN, MWY, NGDLC, NT, RNR, SI, TRI, VRTA.
4 January 2010 - US biotechnology company InterMune Inc (NASDAQ: ITMN) said today that the US Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
(NAH231) W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).
Tickers featured: AMGN, BGEN, BMY, CHIR, GENZ, GILD, ICOS, IDPH, IMCL, IMNX, ITMN, JNJ, PDLI.
Acronyms browser ?
Full browser ?
- ITM Option
- ITM Options
- ITMS (AICPA)
- ITMS AICPA